Compare BridgeBio Pharma Inc (BBIO) vs Extra Space Storage, Inc. (EXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Extra Space Storage, Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Extra Space Storage, Inc. trades at $146.41 (market cap $30.98B). The key difference: Extra Space Storage, Inc. is the larger of the two by market cap, and Extra Space Storage, Inc. pays a 4.42% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | EXR | |
|---|---|---|
Market Cap | $16.61B | $30.98B |
Sector | Health | Real Estate |
52-Week High | $90.17 | $152.85 |
52-Week Low | $47.29 | $126.67 |
Enterprise Value | $18.16B | $44.70B |
Dividend Yield | — | 4.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
EXR trades at $149.54, near its 52-week high, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q2 2026 core FFO of $2.15 per share, exceeding estimates, and raised full-year guidance. Revenue growth remains steady, with a net income margin of 27.79% in 2025, though valuation ratios like P/E of 33.01 suggest a premium pricing.
Outlook is positive with analyst consensus price target of $157.25, but risks include high debt levels and competitive pressures in the self-storage sector. The stock offers a dividend yield supported by solid cash flows, making it attractive for income-focused investors amid cautious market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →
